PharmaShots | Incisive News in 3 Shots

Subscribe Now

KEYNOTE-177

Merck's Reports Results of Keytruda (pembrolizumab) in P-III KEYNOTE-177 for Patients with MSI-H Colorectal Cancer #ASCO20

Merck's Reports Results of Keytruda (pembrolizumab) in P-III KEYNOTE-177 for Patients with MSI-H Colorectal Cancer #ASCO20

June 1, 2020

Merck & Co. Reports Results of Keytruda (pembrolizumab) in P-III KEYNOTE-177 Study for Advanced Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Canc

Merck & Co. Reports Results of Keytruda (pembrolizumab) in P-III KEYNOTE-177 Study for Advanced Microsatellite Instability-Hig...

April 2, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us